Ebselen- SPI-1005
SPI-1005 finished Phase 3 clinical trials with positive results In 2021, I wrote a blog about an investigational new oral drug for treating Ménière’s Disease. Known as SPI-1005, it contains ebselen, a new chemical with antioxidant and anti-inflammatory activity. At the time, participants with a definite history of Ménière’s Disease were recruited for SPI-1005 Phase 3…
Read More
Phase 3 drug trial – a cause for optimism? Every time that I read about a new drug going into clinical trials for the treatment of tinnitus or hearing loss, I tend to do a contained, internal Happy Dance. Recently, I read that the FDA has allowed Sound Pharmaceuticals to proceed with a Phase 3 (human) trial…
Read More